Clinical Trials Logo

Clinical Trial Summary

This study evaluates the effectiveness of the Transcutaneus Electric Nerve Stimulation (TENS) during the labour. TENS is a low frequency electrotherapy technique, analgesic type, generally used in musculoskeletal pathology.

The investigators will have three groups of participants to be administered the TENS, a different dose in two groups, while the third will correspond to placebo.

The hypothesis of the study is to verify if the TENS is effective as a non-pharmacological method in the relief of pain during childbirth


Clinical Trial Description

1. Background:

Pain during labour is one of the most intense pain that many women could experience during their lives, and it can be influenced by the anatomical and physiological factors of the labouring women, and also, by their psychological experiences, as well as by cultural, social, and environmental factors.

Neuraxial analgesia during labour is the most effective method for pain relief, but it appears to be associated with certain side effects, such as maternal hypotension, decreased uteroplacental perfusion, foetal bradycardia, fever, pruritus, an increased oxytocin requirement, a prolonged second stage of labour, a higher rate of operative delivery, and high costs.

The use of non-pharmacological methods for pain relief includes a wide variety of techniques aimed at improving physical sensations and preventing psychoemotional perception of pain. Among the main nonpharmacological methods of pain relief at delivery is the application of Transcutaneous electrical nerve stimulation (TENS). Its application during childbirth is based on the Gait Control theory of pain of Melzack and Wall. According to their theory, the application of TENS reduces the excitability of the delta A and C pain fibers, thus reducing the amount of painful messages ascending the spinal cord. Activation of these fibers stimulates the release of natural pain inhibitors.

Furthermore, many non-pharmacological methods of managing pain increase the satisfaction of women with their childbirth experience.

TENS have used for labour analgesia and there are several studies which show its effectiveness. The effectiveness of TENS depends on the duration, frequency and amplitude of the stimulating current and the site of application of the electrodes. TENS can be administered by either dermatomal stimulation or by stimulation of acupuncture points for labour analgesia. In addition, all studies stated that it was safe and there was no side effects on the mother and the baby.

This work was conducted to study the effectiveness of TENS on labour analgesia, maternal and fetal outcome using TENS by dermatomal stimulation technique. Thus, device will be used as follows:

Through electrodes applied to the lower back, the parturient can control both parameters, the frequency and intensity of the low-voltage electrical impulses emitted from the TENS device. When applying to the lower back, the TENS unit emits electrical impulses which excite afferent nerves, and thus inhibit the transmission of painful stimuli arising from the uterus, vagina and perineum during labour. These electrodes are attached to the skin bilaterally at paravertebral positions T10 and S2.

In the present study the investigators will use three equal devices (two different dose and one placebo) .They will be assigned a number that associate to each group of participants.

Safety profile in the use of TENS:

It is a non-invasive technique, easy to administer, without side effects or interactions with other drugs, it cannot produce toxicity in the tissue or cellular level.

The current literature does not reflect any complications, either on the part of the pregnant woman and in the fetus, during the application of TENS in the labor phase.

The use of TENS should be contraindicated in women whose gestational age does not exceed 37 weeks, women with pacemakers and water births. It should not be applied in the maternal abdomen, at any time during pregnancy or childbirth, to avoid stimulation near the fetal heart.

2. Objectives:

Primary aim:

- To know if the application of TENS is effective in reducing pain during childbirth.

Secondary aim:

- To determine the most effective dose in the use of TENS in pregnant women during labor.

- To analyze the degree of satisfaction of the pregnant women who participate in the study.

- To evaluate whether the use of TENS reduces the dose of the painkillers during childbirth.

3. Material and Methods:

This study is a triple blind randomized trial with concealed allocation, assessor blinding for some outcomes, and intention-to-treat analysis.

It was accepted by the Ethic Committee of the Hospital Complejo Hospitalario Universitario Insular Materno Infantil of Las Palmas de Gran Canaria, Canary Islands, Spain, with registration number CEIm-CHUIMI-2016/875.

3.1. Allocation: All participants will be recruited from a group of women admitted to the hospital. If the pregnant woman meets the inclusion criteria, she will be asked to participate in the study. If yes, they must sign the informed consent, approved by the same ethical committee of the hospital.

The assignment to each group was made through the website www.random.org to perform randomization. In addition, each group has a different TENS, which has the group number. Participants in all groups will receive all the other routine obstetric care.

3.2. Sample size determination: The sample size and power calculations were performed using the software GRANMO 7.11. Calculations were based on detecting differences of 2 units in a 10 numerical pain rate scale at post-data, assuming a standard deviation of 1.9, a 2-tailed test, an alpha level of 0.05, and a desired power of 80%. These assumptions generated a sample size of 63 subjects, 21 per group.

There is a specialiced nurse that will supervised the correct functionality every day. He will be responsible for resolving dispositive problems like low charge or insufficient electrodes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03137251
Study type Interventional
Source University of Las Palmas de Gran Canaria
Contact
Status Completed
Phase N/A
Start date May 1, 2017
Completion date September 30, 2018

See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02528136 - The Clinical Carbetocin Myocardium Trial Phase 4